Transient response of cardiac angiosarcoma to paclitaxel

Eur J Cancer Care (Engl). 2010 Sep;19(5):699-700. doi: 10.1111/j.1365-2354.2009.01084.x. Epub 2009 Nov 11.

Abstract

Malignant tumours of the heart are a group of tumours with low incidence but very high mortality. Delays in diagnosis are common because of their multiple forms of presentation, and 80% present with metastases, further reducing the possibility for cure. We present here the case of a patient with primary cardiac angiosarcoma that highlights the misdiagnosis at clinical presentation, current diagnostic modalities and a possible new treatment using paclitaxel for cardiac angiosarcoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Fatal Outcome
  • Heart Neoplasms / drug therapy*
  • Hemangiosarcoma / drug therapy*
  • Humans
  • Male
  • Paclitaxel / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel